EUVIMEDEUVIMED entdecken
Crossref

Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC

María Fernanda Guerra-Veloz iD, Sital Shah, Beatrice Emmanouil, Mia Olsen, Renita George, Sarah Selemani, Paul J Ross, Ivana Carey, Neha Mehta, Mark Gillyon-Powell, Kosh Agarwal iD

Journal of Viral Hepatitis · 2026

DOI: 10.1111/jvh.70148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2026. Verfasst von María Fernanda Guerra-Veloz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Liver Studies, King's College Hospital, London, UK. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis C, Chronic. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effectiveness of direct acting antiviral (DAA) therapy in patients with active hepatocellular carcinoma (HCC) is poorly defined. NHS England approved DAA therapy for all viraemic patients, including those with HCC. The aim of this retrospective study is to provide a real‐life data of treatment outcomes in those with active HCC. Patients with HCV related HCC from the National Hepatitis C registry in South‐East England between 2016 and 2023 were included. The primary outcome was to assess the HCV care cascade in patients with HCV related HCC (HCC cohort) in comparison with those with advanced fibrosis/cirrhosis without HCC (non‐HCC cohort). 1518 HCV RNA‐positive patients started DAA therapy. 92.4% (1403) were included in the non‐HCC cohort and 7.6% (115) were included in the HCC cohort. The SVR rate in the HCC cohort was 87% (80/92) versus 94.5% (1126/1191) in the non‐HCC cohort ( p = 0.003). In the multivariate analysis, only the presence of HCC (OR 0.4 95% CI 0.2–0.9; p = 0.029) was associated with a lower probability of achieving SVR. SVR rates were 95.6%, 50%, 75% and 22.2% and the median overall survival (OS) was 80, 29, 17 and 3 months for BCLC 0‐A/B/C/D respectively. OS was longer in those who achieved SVR. More than two thirds of patients with HCV‐related HCC initiated and completed DAA therapies. This high level of treatment uptake has led to an acceptable cure rate. Treating patients with HCV and HCC should be viewed as an appropriate clinical standard to improve overall outcomes. However, DAA therapy should not be initiated in those with a short life expectancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularAntiviral AgentsLiver NeoplasmsHepatitis C, ChronicHumansRetrospective StudiesTreatment OutcomeSustained Virologic ResponseFemaleMaleMiddle AgedAgedEnglandHepacivirusRegistries

Stichwörter der Autor:innen

DAA therapyhepatitis C care cascadehepatocellular carcinomaoverall survivalsustained virological response

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Institute of Liver Studies, King's College Hospital, London, UK.
  • NHS England & NHS Improvement, HCV Elimination, London, UK.
  • Department of Oncology, King's College Hospital NHS Foundation Trust, London, UK.

ORCID-Profile: María Fernanda Guerra-Veloz, Kosh Agarwal

Zitieren

APA

Guerra-Veloz, M. F., Shah, S., Emmanouil, B., Olsen, M., George, R., Selemani, S., Ross, P. J., Carey, I., Mehta, N., Gillyon-Powell, M., & Agarwal, K. (2026). Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70148

Vancouver

Guerra-Veloz MF, Shah S, Emmanouil B, Olsen M, George R, Selemani S, et al. Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC. Journal of Viral Hepatitis. 2026. doi:10.1111/jvh.70148

BibTeX
@article{GuerraVeloz2026,
  author = {Guerra-Veloz, María Fernanda and Shah, Sital and Emmanouil, Beatrice and Olsen, Mia and George, Renita and Selemani, Sarah and Ross, Paul J and Carey, Ivana and Mehta, Neha and Gillyon-Powell, Mark and Agarwal, Kosh},
  title = {Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  doi = {10.1111/jvh.70148}
}
Kostenlos starten →